A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma (NCT05888844)

🧪 Interventions in This Study

• INCB099280 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (77 Sites)

Showing the first 25 of 77 sites.

• Border Medical Oncology Research Unit — Albury, New South Wales
• Townsville Cancer Centre — Townsville, Queensland
• Princess Alexandra Hospital Australia — Woolloongabba, Queensland
• Box Hill Hospital — Box Hill, Victoria
• Monash Medical Centre Clayton — Clayton, Victoria
• Fundacao Pio Xii Hospital de Cancer de Barretos — Barretos,
• Cepen - Centro de Pesquisa E Ensino Em Oncologia de Santa Catarina — Florianópolis,
• Oncosite - Centro de Pesquisa Clinica E Oncologia — Ijuí,
• Fundacao Doutor Amaral Carvalho — Jaú,
• Hospital Sao Vicente de Paulo — Passo Fundo,
• Irmandade Da Santa Casa de Misericordia de Porto Alegre — Porto Alegre,
• Hgb - Hospital Giovanni Battista - Mae de Deus Center — Porto Alegre,
• Instituto de Oncologia Saint Gallen — Santa Cruz do Sul,
• Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia — Santo André,
• A. C. Camargo Cancer Center — São Paulo,
• Q.E. Ii Health Sciences Centre — Halifax, Nova Scotia
• McGill University Jewish General Hospital — Montreal, Quebec
• Cdiem - Centro de Investigacion Y Especialidades Medicas — Santiago,
• James Lind Centro de Investigacion Del Cancer — Temuco,
• Clinical Research Chile Spa. — Valdivia,
• Specialty Hospital Medico — Rijeka,
• University Hospital Centre Sestre Milosrdnice — Zagreb,
• Avicenne Hospital — Bobigny,
• Bordeaux Chu Hopital Saint - Andre — Bordeaux,
• Hospital Ambroise Pare — Boulogne-Billancourt,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cutaneous Squamous Cell Carcinoma

• Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer — La Jolla, California
• A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer — Aurora, Colorado
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Gilbert, Arizona
• Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma — Houston, Texas
• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — Boston, Massachusetts

Explore by condition: All Cutaneous Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.